Meiji Pays 80% Premium for $50 Million Stake in Arcturus
Meiji Seika Pharma pays $20.27 per share, an 80% premium, for a 7.9% stake in Arcturus Therapeutics, alongside a new ARCT-154 license and a Japan pandemic MOU.
Topic
Topic
Meiji Seika Pharma pays $20.27 per share, an 80% premium, for a 7.9% stake in Arcturus Therapeutics, alongside a new ARCT-154 license and a Japan pandemic MOU.